The Discounted Cash Flow (DCF) valuation of CRISPR Therapeutics AG (CRSP) is (196.27) USD. With the latest stock price at 53.69 USD, the upside of CRISPR Therapeutics AG based on DCF is -465.6%.
Based on the latest price of 53.69 USD and our DCF valuation, CRISPR Therapeutics AG (CRSP) is a sell. selling CRSP stocks now will result in a potential gain of 465.6%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.8% - 7.5% | 6.6% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (655.34) - (119.35) | (196.27) |
| Upside | -1320.6% - -322.3% | -465.6% |